Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Closing Knowledge Gaps to Optimize Patient Outcomes and Advance Precision Medicine.

Giusti K, Young AQ, Lehrhaupt K.

Cancer J. 2018 May/Jun;24(3):144-151. doi: 10.1097/PPO.0000000000000319. Review.

PMID:
29794540
2.

The Multiple Myeloma Research Foundation's evolving focus on drug R&D.

Giusti K.

Nat Biotechnol. 2012 Jul 10;30(7):600-3. doi: 10.1038/nbt.2297. No abstract available.

PMID:
22781678
3.

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.

Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC.

Br J Haematol. 2012 Aug;158(4):472-80. doi: 10.1111/j.1365-2141.2012.09173.x. Epub 2012 May 29.

4.

Company Profile: Multiple Myeloma Research Foundation.

Giusti K.

Per Med. 2012 May;9(3):333-336. doi: 10.2217/pme.12.25.

PMID:
29758781
5.

One foundation's strategy to accelerate drug discovery through genomics.

Perkins LM, Young AQ, Giusti K.

Sci Transl Med. 2011 Apr 13;3(78):78cm11. doi: 10.1126/scitranslmed.3002440.

PMID:
21490273
6.

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.

Stewart AK, Chang H, Trudel S, Anderson KC, Richardson P, Alsina M, Reece D, Young S, Sable-Hunt A, Li Z, Keats J, Van Wier S, Ahmann G, Price-Troska T, Giusti K, Bergsagel PL, Chesi M, Fonseca R.

Leukemia. 2007 Nov;21(11):2358-9. Epub 2007 Jun 14. No abstract available.

7.

The Multiple Myeloma Research Foundation: Educating the Myeloma Community on Recent Treatment Innovations.

Giusti K.

J Oncol Pract. 2005 Jul;1(2):76. doi: 10.1200/jop.2005.1.2.76. No abstract available.

Supplemental Content

Loading ...
Support Center